Novo Nordisk A/S (NYSE:NVO) Shares Down 2.5% – What’s Next?

Novo Nordisk A/S (NYSE:NVO) fell 2.5% during mid-day trading on Wednesday . The company traded as low as $37.00 and last traded at $37.4760. 25,317,597 shares changed hands during mid-day trading, an increase of 1% from the average session volume of 25,111,252 shares. The stock had previously closed at $38.43.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Sanford C. Bernstein initiated coverage at “outperform” with a $175 price target — a very bullish stamp that can attract buyers and support shares despite recent weakness.
• Positive Sentiment: A new study found stopping GLP‑1 therapy raises risks of heart attack, stroke and death in Type 2 diabetes patients, reinforcing the clinical value and stickiness of GLP‑1 drugs like semaglutide (Wegovy/Ozempic), which supports long‑term demand. Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says
• Positive Sentiment: Partnerships expanding access (e.g., Hims & Hers distribution of GLP‑1s) could broaden patient reach and support steady volume growth for Novo’s obesity/diabetes portfolio. Novo Nordisk (NVO) Partners With Hims & Hers, Here’s What You Need to Know
• Neutral Sentiment: Commentary pieces are debating whether the recent price decline makes NVO a value buy; that keeps investor attention high but creates mixed flows as value and momentum investors disagree. Is Novo Nordisk (NYSE:NVO) Starting To Look Interesting After A 52% One Year Slide?
• Negative Sentiment: New clinical data from a rival oral GLP‑1 (aleniglipron) showed weight‑loss results comparable to Wegovy, increasing competitive pressure in obesity — a direct threat to pricing and market share. Rival GLP-1 pill matches Wegovy weight loss data, adding to competitive pressure on Novo Nordisk
• Negative Sentiment: Reports say Novo Nordisk stands to lose key semaglutide patent protection in India soon, opening the door to low‑cost generics in a large, price‑sensitive market — a risk to long‑term sales and margin assumptions. Novo Nordisk Patent Loss In India Tests GLP 1 Valuation Story
• Negative Sentiment: The Portnoy Law Firm has opened an investigation into possible securities fraud involving Novo Nordisk, a headline that can prompt selling pressure and increase short‑term volatility. Novo Nordisk A/S Investigated by the Portnoy Law Firm

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. TD Cowen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price objective on the stock. in a research note on Tuesday, March 10th. Finally, CICC Research began coverage on Novo Nordisk A/S in a research report on Friday, January 9th. They set an “outperform” rating and a $73.50 target price on the stock. Four equities research analysts have rated the stock with a Buy rating and nineteen have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Stock Down 2.5%

The company has a market cap of $167.33 billion, a price-to-earnings ratio of 10.80 and a beta of 0.74. The stock’s 50-day moving average is $49.45 and its 200-day moving average is $51.48. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The business had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. On average, analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The company also recently announced a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be given a $1.2751 dividend. This represents a yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s payout ratio is presently 52.74%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. True Wealth Design LLC grew its stake in Novo Nordisk A/S by 209.8% in the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after acquiring an additional 300 shares during the period. Guerra Advisors Inc bought a new position in shares of Novo Nordisk A/S in the 3rd quarter worth $25,000. Godfrey Financial Associates Inc. bought a new position in shares of Novo Nordisk A/S in the 4th quarter worth $25,000. WealthCollab LLC grew its position in Novo Nordisk A/S by 93.5% in the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after purchasing an additional 260 shares during the period. Finally, American National Bank & Trust acquired a new stake in Novo Nordisk A/S in the 4th quarter valued at $28,000. Institutional investors own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.